• 16

    December 2020 - Frontiers in Cellular and Infection Microbiology

    Trypanosoma cruzi, Trypanosoma brucei and Leishmania are parasitic protozoan causing Chagas disease, African Trypanosomiasis and Leishmaniases worldwide. During the parasite-host interaction, those organisms release extracellular vesicles (EVs) that are crucial for the immunomodulatory events triggered by the parasites. EVs are involved in cell-cell communication and can act as important pro-inflammatory mediators.

  • 15

    August 2020 - The Canadian Veterinary Journal 

    A mixed breed dog rescued from Morocco was presented at a Quebec veterinary practice for facial lesions. Genomic DNA extraction from blood samples and polymerase chain reaction (PCR) were used to confirm L. infantum parasitemia.  Key clinical message: Diagnosis of tropical diseases in Canada will likely become more common in the near future.

  • 14

    August 2020 - PLOS Neglected Tropical Diseases

     Knowing that the composition of extracellular vesicles (EVs) can vary according to the state of their parental cell, we hypothesized that EVs released by drug-resistant Leishmania infantum parasites could contain unique and differently enriched proteins depending on the drug-resistance mechanisms involved in the survival of their parental cell line. 

  • 13

    June 2020 - Genes

    Leishmaniasis (Leishmania species), sleeping sickness (Trypanosoma brucei), and Chagas disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by trypanosomatid parasites. At present, drugs for treating trypanosomatid diseases are far from ideal due to host toxicity, elevated cost, limited access, and increasing rates of drug resistance.

  • 12

    MRPA-INDEPENDENT MECHANISMS OF ANTIMONY RESISTANCE IN Leishmania infantum

    April 2020 - International Journal for Parasitology: Drugs and Drug Resistance

    Control of both human and canine leishmaniasis is based on a very short list of chemotherapeutic agents, headed by antimonial derivatives (Sb). The utility of these molecules is severely threatened by high rates of drug resistance. The ABC transporter MRPA is one of the few key Sb resistance proteins described to date, whose role in detoxification has been thoroughly studied in Leishmania parasites.

  • 11

    EFFECTS OF RECYCLED MANURE SOLIDS BEDDING ON THE SPREAD OF GASTROINTESTINAL PARASITES IN THE ENVIRONMENT OF DAIRIES AND MILK

    August 2019 - Journal of Dairy Science

    The aim of this work was to isolate common bovine digestive tract parasites in recycled manure bedding (RMS), as well as to determine the ability of current RMS preparation procedures to eliminate these pathogens.

  • 10

    Leishmania (Viannia) guyanensis

    July 2019 - Trends in Parasitology

    Leishmania of the Viannia subgenus, including Leishmania Viannia guyanensis, is the agent responsible for cutaneous and mucocutaneous leishmaniasis (CL and MCL) in the Americas from the USA to Argentina. 48 000 new cases of Cl and MCL are reported yearly.

  • 09

    REPURPOSED MOLECULES: A NEW HOPE IN TACKLING NEGLECTED INFECTIOUS DISEASES

    July 2019 - In Silico Drug Design. Repurposing Techniques and Methodologies

    Neglected infectious diseases (NIDs) are a group of chronic, debilitating, and poverty-promoting diseases, which include parasitic, bacterial, viral, and fungal infections.

  • 08

    INNOVATIVE SOLUTIONS FOR THE CONTROL OF LEISHMANIASES: NANOSCALE DRUG DELIVERY SYSTEMS

    June 2019 - Current Pharmaceutical Design

    Leishmania numerous forms (cutaneous, mucocutaneous, and visceral) are currently treated with a sparse arsenal of drugs, specifically antimonials, amphotericin B, miltefosine, and paromomycin, for which drug resistance and clinical failure are rampant. Medicine is presently trending towards nanotechnology to aid in the successful delivery of drugs. 

  • 07

    Leishmania AND ITS EXOSOMAL PATHWAY: A NOVEL DIRECTION FOR VACCINE DEVELOPMENT

    Mars 2019 - Future Medicine

    Protozoan parasites still affect over 100 million organisms on our planet, including both humans and animals. While various drugs have been developed in efforts to control or cure several pathogens responsible for various disease types such as malaria, leishmaniasis, and trypanosomiasis, effective vaccines have yet to be developed against these parasites of critical medical and veterinary importance.

  • 06

    A REVIEW OF THE CURRENT EVIDENCE OF FRUIT PHENOLIC COMPOUNDS AS POTENTIAL ANTIMICROBIALS AGAINTS PATHOGENIC BACTERIA

    Mars 2019 - Microbial Pathogenesis

    Fruits are among the main natural sources of phenolic compounds (PC). This review discusses by first time the available literature regarding the inhibitory effects of fruit PC on pathogenic bacteria, including not only their direct effects on bacterial growth and survival, but also their effects on virulence factors and antibiotic resistance, as well as the possible mechanism underlying these inhibitory properties.

  • 05

    COS-SEQ: A HIGH-THROUGHPUT GAIN-OF-FUNCTION SCREEN FOR DRUG RESISTACE STUDIES IN Leishmania

    April 2019 - Methods in Molecular Biology

    In order to improve knowledge about the mode of action of current drugs against Leishmania and those in development, and the mechanisms pertaining to their resistance, we recently described a sensitive and high-throughput method termed Cos-Seq. Here we provide a detailed protocol.

  • 04

    HIGH-THROUGHPUT IDENTIFICATION AND QUANTIFICATION OF Haemonchus contortus IN FECAL SAMPLES

    November 2018 - Veterinary Parasitology

    The goal of this study was to facilitate and accelerate the identification and quantification of Haemonchus contortus in fecal samples through the use of fluorescein-isothiocyanate peanut-agglutininstaining in order to allow automated detection using a 96-well microplate reader. 

  • 03

    HIGH-THROUGHPUT COS-SEQ SCREEN WITH INTRACELLULAR Leishmania infantum FOR THE DISCOVERY OF NOVEL DRUG-RESISTANCE MECHANISMS

    Mars 2018 - International Journal for Parasitology: Drugs and Drug Resistance

    Increasing drug resistance towards first line antimony-derived compounds has forced the use of novel therapies in endemic leishmaniasis (amphotericin B and miltefosine). In order to discover stage-dependent resistance genes, we have adapted the Cos-Seq approach through the introduction of macrophage infections in the pipeline.

  • 02

    OMICS AND THEIS IMPACT ON THE DEVELOPMENT OF CHEMOTHERAPY AGAINST LEISHMANIA

    October 2017 - In: Drug Discovery fo Leishmaniasis. The Royal Society of Chemistry

    Omics-based studies represent a major step forward in the analysis of modes of action and resistance mechanisms of drugs in Leishmania parasites, the causative agents of the leishmaniases. These are two key considerations when developing or repurposing drugs for chemotherapy against these neglected tropical diseases. 

  • 01

    DIFFERENT MUTATIONS IN A P-type ATPase TRANSPORTER IN LEISHMANIA PARASITES ARE ASSOCIATED WITH CROSS-RESISTANCE TO TWO LEADING DRUGS BY DISTINCT MECHANISMS

    December 2016 - PLoS Neglected Tropical Diseases

    Liposomal amphotericin B (AmB) followed by a short administration of miltefosine (MF) is a drug combination effective for treating visceral leishmaniasis in endemic regions of India. Resistance to MF can be due to point mutations in the miltefosine transporter (MT). Here we show that mutations in MT are also observed in Leishmania AmB-resistant mutants.

©2019 by CFP Lab